{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:50Z","timestamp":1786119470592,"version":"build-2736575974"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1097\/crd.0b013e3181f4a6a2","type":"journal-article","created":{"date-parts":[[2010,12,3]],"date-time":"2010-12-03T04:09:18Z","timestamp":1291349358000},"page":"41-44","source":"Crossref","is-referenced-by-count":19,"title":["Vernakalant"],"prefix":"10.1097","volume":"19","author":[{"given":"David","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210203","doi-asserted-by":"crossref","first-page":"436","DOI":"10.2174\/156802609788340832","article-title":"Kv1.5 Blockers for the treatment of atrial fibrillation: approaches to optimization of potency and selectivity and translation to in vivo pharmacology.","volume":"9","author":"Bilodeau","year":"2009","journal-title":"Curr Topic Med Chem"},{"key":"R2-8-20210203","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1345\/aph.1K542","article-title":"Vernakalant in the management of atrial fibrillation.","volume":"42","author":"Cheng","year":"2008","journal-title":"Ann Pharmacother"},{"key":"R3-8-20210203","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1517\/13543784.17.5.805","article-title":"Vernakalant\u2014a promising therapy for conversion of recent-onset atrial fibrillation.","volume":"17","author":"Naccarelli","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"R4-8-20210203","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10840-008-9269-3","article-title":"New anti-arrhythmic drugs for atrial fibrillation: focus on dronedarone and vernakalant.","volume":"23","author":"Camm","year":"2008","journal-title":"J Interv Card Electrophysiol"},{"key":"R5-8-20210203","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.cardiores.2006.01.026","article-title":"RSD1235 blocks late Ina and suppresses early after depolarization and torsades de pointes induced by class III agents.","volume":"70","author":"Orth","year":"2006","journal-title":"Cardiovasc Res"},{"key":"R6-8-20210203","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/j.1540-8167.2005.50028.x","article-title":"The mechanism of atrial antiarrhythmic action of RSD1235.","volume":"16","author":"Fedida","year":"2005","journal-title":"J Cardiovasc Electrophysiol"},{"key":"R8-8-20210203","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1517\/13543784.16.4.519","article-title":"Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent.","volume":"16","author":"Fedida","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"R9-8-20210203","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/0091270008325148","article-title":"Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.","volume":"49","author":"Mao","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"R10-8-20210203","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/FJC.0b013e3180547553","article-title":"The effect of vernakalant (RSD1235), an investigational anti-arrhythmic agent, on atrial electrophysiology in humans.","volume":"50","author":"Dorian","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"R11-8-20210203","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2004.09.021","article-title":"CRAFT Investigators. A randomized, controlled trial of RSD 1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.","volume":"44","author":"Roy","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R13-8-20210203","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1161\/CIRCULATIONAHA.107.723866","article-title":"Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation. A phase 3, randomized, placebo-controlled trial.","volume":"117","author":"Roy","year":"2008","journal-title":"Circulation"},{"key":"R14-8-20210203","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/CIRCEP.109.870204","article-title":"Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery.","volume":"2","author":"Kowey","year":"2009","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"R17-8-20210203","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0140-6736(10)60096-7","article-title":"New antiarrhythmic drugs for treatment of atrial fibrillation.","volume":"375","author":"Dobrev","year":"2010","journal-title":"Lancet"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0b013e3181f4a6a2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:36:49Z","timestamp":1786041409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045415-201101000-00008"}},"subtitle":["A New Drug to Treat Patients With Acute Onset Atrial Fibrillation"],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0b013e3181f4a6a2","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}